ADC Therapeutics Corp (ADCT) Total Debt to Capital

ADC Therapeutics SA - graphic logo of issuer ADCT

ADC Therapeutics (ADCT) is optimizing expenses by outsourcing drug manufacturing and clinical trials to third-party contractors. Business revenues are based on the sale of ZYNLONTA for lymphoma therapy. The implementation of automated laboratory systems is accelerating genetic analysis. The price action for the total debt-to-equity ratio is 0.00, as clearly illustrated in the chart below for ADCT.

adctherapeutics.com (ADCT): Debt to Equity Ratio from 07/04/2022 to 10/31/2026

Metric breakdowns and analytics for ADC Pharma (ADCT)

- share price and consensus valuation forecast:
Stock Price ADC Therapeutics SA|ADCT - Consensus Target
- market capitalization details:
Market Capitalization ADC Therapeutics|ADCT - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share ADC Therapeutics|ADCT - Accounting Capitalization|Market Capitalization to Book Value Ratio adctherapeutics.com|ADCT - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital ADC Therapeutics|ADCT - Long-Term Liabilities to Capital|Short-Term Debt to Equity ADC Therapeutics|ADCT - Aggregate Debt Obligations|Debt to Book Value ADC Therapeutics|ADCT - Company Long-Term Loans and Borrowings|Company Short-Term Debts ADC Therapeutics|Quick Liquidity adctherapeutics.com
- net income and valuation ratios data:
ADCT - Company Net Income
Fundamental company valuation:ADC Therapeutics SA
Finished products of ADC Therapeutics

The ratio is calculated as total liabilities divided by equity, providing a real-time assessment of changes in financial stability. This metric determines the extent of the business's reliance on borrowed funds relative to shareholder equity. For ADC Therapeutics (ADCT), leverage is critical when financing robotic laboratories and high-throughput biomolecule screening. A high ratio signals risks of asset impairment. By analyzing the trend of the total debt-to-equity ratio, an investor evaluates the balance between growth and solvency.

Competitor analysis for ADC Therapeutics

TGTX (TG Therapeutics) - Total Debt to Capital|Total Debt to Equity Ratio Arcellx Inc (ACLX)|Total Debt to Capital IRON|Total Debt to Capital Syndax Corp (SNDX)|Debt to Equity Kura Oncology, Inc. KURA|FHTX: Debt to Equity Ratio|Vor Biopharma - Total Debt to Capital|Nkarta, Inc. (NKTX) - Total Debt to Equity Ratio|COEP: Total Debt to Capital|Debt to Capital Actinium Corp (ATNM)|Debt to Equity Estrella Immunopharma|CASI: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio MRKR (Marker Therapeutics)|INAB (IN8bio Inc.) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital ERNA (Eterna Therapeutics Inc.)|GT Biopharma Corporation - Debt to Equity|APTO - Debt to Equity|BPTH: Debt to Equity|MEI Pharma (MEIP) - Debt to Equity|Debt to Capital Vincerx Pharma (VINC)